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ABSTRACT
An effective treatment already exists for many diseases. In
these cases the effectiveness of a new treatment may be
established by showing that the new treatment is as effec-
tive as (i.e., equivalent to) or at least as effective as (i.e.,
noninferior to) the old treatment. For an economic evalua-
tion accompanying a clinical equivalence or noninferiority
trial it is important to decide before the start of the study
on the appropriate research question. In many cases the
objective of the economic evaluation will be to show
equivalence or noninferiority of the cost-effectiveness of the
treatments. This has major implications for the design and
analysis of the economic evaluation. In this article we
propose methods for the analysis of economic equivalence
and noninferiority studies that are similar to the methods
applied to clinical equivalence and noninferiority trials. Fur-
thermore, cost-effectiveness planes prove to be a valuable
tool in the interpretation of the results in an economic
equivalence or noninferiority trial. The concepts described
in the article are illustrated using the results from an eco-
nomic noninferiority trial.
Keywords: cost-effectiveness analysis, depression, economic
evaluation, research methodology.
Introduction
For many diseases effective treatments already exist. In
these cases the research question of a study investigat-
ing these different treatment options may not be which
treatment option is the superior one, but whether
the different options are approximately equal to each
other. Thus, the effectiveness of a new treatment may
be established by showing that the new treatment is as
effective as (i.e., equivalent to) or at least as effective as
(i.e., noninferior to) the old treatment that was already
shown to be effective, while having advantages like less
side effects or an easier dose regimen for example. For
clinical analyses there is much literature on the design
and analysis of such so-called equivalence trials. Nev-
ertheless, there are also cases in which one wants to
demonstrate that two treatments are not only clini-
cally, but also economically equivalent. Therefore,
when conducting an economic evaluation alongside an
equivalence or noninferiority trial, it is important to
determine the appropriate research question before-
hand. When the objective is to evaluate whether one of
the two treatments in a clinical equivalence or non-
inferiority trial has signiﬁcantly lower costs a cost
minimization analysis is indicated. Nevertheless, a
drawback of cost minimization analyses is that costs
alone are considered and not both costs and effects.
Moreover, it is often relevant for decision-makers to
know whether the new treatment is as expensive as
(i.e., equivalent to) or not more expensive than (i.e.,
noninferior to) the old treatment. For example, in a
trial comparing antidepressant treatment with psycho-
therapy in depression, it is relevant for doctors to
know that both treatments are equivalent or at least
noninferior in both clinical and economic aspects. The
choice of treatment can then be based on other aspects,
like the patient’s preference. This is also true for a trial
comparing two or more medications, for example two
antidepressants from different pharmaceutical classes.
The objective of this article is to describe the conse-
quences for the design and analysis of an economic
evaluation assessing equivalence or noninferiority of
costs and cost-effectiveness.
Introduction to the Example Trial
Concepts described in this article are illustrated using
the results from a noninferiority trial we performed. In
this randomized trial we compared standardized usual
care by the general practitioner (GP) with and without
antidepressants in patients with minor depressions.
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The rationale for starting this trial was that antidepres-
sants are often prescribed although there is insufﬁcient
evidence for their effectiveness in this group of
patients. When antidepressants have no additional
beneﬁts in terms of health effects over standardized
usual care alone in patients with minor depressions
disadvantages of antidepressant use such as adverse
effects, labeling, medicalization, dependency, and costs
prevail. Thus, if standardized usual care alone is at
least as effective as standardized usual care plus anti-
depressants the prescription of antidepressants in this
group of patients does not seem justiﬁed. One would
expect that addition of antidepressants to standardized
usual care by the GP is more expensive than standard-
ized usual care alone. Nevertheless, it is also plausible
to assume that patients who do not receive antidepres-
sants, make more use of other medication and other
health-care services. Thus, from an economic perspec-
tive, if standardized usual care alone is not more
expensive than standardized usual care plus antide-
pressants routine prescription of antidepressants does
not seem justiﬁed. Therefore, the hypothesis in the
economic evaluation was that standardized usual care
alone is at least as effective as and not more expensive
than (i.e., noninferior to) standardized usual care plus
antidepressants.
Patients who were diagnosed with minor or mild-
major depression by their GP were eligible for the trial.
Excluded were patients who were 17 years old or
younger who currently received some form of de-
pression treatment, who had comorbid psychiatric
disorders or who were unable to complete the ques-
tionnaires. All patients received four consultations
with their GP during which they received advice and
support (standardized usual care). Half of the patients
were randomly allocated to receive an antidepressant
(standardized usual care plus antidepressants). In total,
181 patients were included in the study (standardized
usual care: 96 patients, standardized usual care plus
antidepressants: 85 patients). There were no differ-
ences in baseline sociodemographic and clinical
characteristics between the two treatment groups.
Complete cost data were available for 89 patients.
Patients with complete follow-up were more likely to
be previously treated for depression or to have Dutch
origins and were less depressed at baseline. Results
from an imputed analysis did not differ from the com-
plete case analysis.
Design and Analysis of Clinical Equivalence and
Noninferiority Trials
Design
The aim of a clinical equivalence trial is to show the
therapeutic equivalence of two treatments [1]. Absence
of a statistically signiﬁcant difference between the
treatments compared in a randomized controlled trial
does not imply equivalence of the treatments [2].
Moreover, in trials with large sample sizes, it is pos-
sible to demonstrate a small, but statistically signiﬁ-
cant difference between treatment groups that is
clinically unimportant.
In equivalence trials the hypothesis is that the new
treatment and the control treatment are equally effec-
tive, as opposed to superiority trials where the hypoth-
esis is that the new treatment is more effective than the
control treatment. In an equivalence trial a clinically
acceptable difference, d, has to be determined a priori.
Because the aim of the study is to show that the new
treatment is sufﬁciently similar to the old treatment d
has to be selected so that any clinically unimportant
difference is smaller than d [1,3].
Analysis
If we have a predeﬁned range of equivalence from –d to
d, equivalence is demonstrated if the two-sided conﬁ-
dence interval around the observed difference between
the two treatment groups lies entirely in this range of
equivalence. Before the start of an equivalence study,
a two-sided a (i.e., the signiﬁcance level) has to be
deﬁned. For measures where higher scores indicate
improvement noninferiority is demonstrated if the
lower limit of the one-sided conﬁdence interval around
the observed difference between the two treatment
groups is equal to or greater than –d (noninferiority
margin). In a noninferiority study a one-sided a is
used, which also has to be deﬁned beforehand [1,4].
The European Agency for the Evaluation of Medicinal
Products recommends using a one-sided a of 2.5% or
a two-sided a of 5% [5]. After demonstrating equiva-
lence or noninferiority, it is still possible to test for
superiority of effects [4]. In traditional superiority
trials statistical superiority is shown if the conﬁdence
interval around the difference in costs or effects does
not contain zero. Clinically meaningful superiority for
measures where higher scores indicate improvement
can be shown if the lower limit of the conﬁdence
interval around the difference in effects is greater than
d. This approach of checking the location of the con-
ﬁdence interval in relation to –d and d is demonstrated
in Figure 1.
In superiority trials the intention-to-treat analysis is
generally conservative, because inclusion of protocol
violators and withdrawals tends to make the two treat-
ment groups more similar. This means that there is a
strong incentive in superiority trials to strictly adhere
to the study protocol. Nevertheless, in an equivalence
trial any blurring of the difference between the treat-
ment groups increases the chance of ﬁnding equiva-
lence, although in reality the trial may have had poor
discriminatory power. Hence, in an equivalence trial
the intention-to-treat analysis is no longer conserva-
tive. Because the per-protocol analysis includes only
patients who properly followed the study protocol this
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analysis is expected to enhance any difference between
the treatment groups and thus to decrease the chance
of declaring equivalence. For this reason it is recom-
mended to carry out both an intention-to-treat and a
per-protocol analysis in an equivalence trial, where the
per-protocol analysis gives the most conservative esti-
mate of the treatment effect. Nevertheless, there are
circumstances when the protocol analysis is biased
toward a conclusion of equivalence or noninferiority.
This is the case if, for example, patients who do not
respond to one of the two treatments drop out early.
Therefore, it is important to examine the subgroup of
patients excluded from the per protocol analysis care-
fully to make sure there is no selective drop out. More-
over, a higher withdrawal rate in one of the treatment
groups because of lack of improvement is an indication
in itself that the treatments are not equivalent or non-
inferior [1]. Because in general it will be more difﬁcult
to demonstrate equivalence in the per-protocol popu-
lation, sample size calculations should be based on this
population [1,3,5,6].
Economic Evaluations Alongside Equivalence
and Noninferiority Trials
Economic Equivalence Margin
In studies where the objective is to show equivalent or
noninferior costs and cost-effectiveness, the approach
is similar to the one applied in clinical equivalence or
noninferiority studies. Before the start of the study,
an acceptable difference in total costs, q, should be
deﬁned. q has to be selected so that any economically
unimportant difference in costs is smaller than q.
One way to determine q may be by deﬁning a rel-
evant difference in resource use. Subsequently, this dif-
ference in resource use can be valued, preferably using
standard costs. Finally, to get q, the different cost cat-
egories are added. When performing the study from a
societal perspective, it is the opportunity cost of any
difference in resource use that is important. Therefore,
it is important to include all relevant direct and indi-
rect costs in the determination of q.
Another approach to deﬁne q may be to equal q to
a percentage of the available health-care budget. In all
cases q should not be too small or too large in com-
parison with the expected total costs. For example, a
cost difference of €25 will not be relevant when the
expected total costs are approximately €5000, but will
be relevant when the expected total costs are around
€250. As qmay vary depending on the context, setting,
and location of the study and on the prevalence of the
disorder under study, it is important to perform some
kind of sensitivity analysis to investigate the uncer-
tainty surrounding q. An approach to this is proposed
in the section “Analysis” below.
In our example trial we used studies from literature
and studies we previously performed to determine a
relevant difference in resource use from a societal per-
spective. This resulted in a relevant difference of two
visits to the GP, one outpatient visit, and 3 days of
absenteeism from paid labor. Using Dutch guideline
prices [7] that were adjusted for 2002 using consumer
price index ﬁgures [8] and after rounding off upwards,
this resulted in amean cost difference of €500. The same
approach can be usedwhen the study is performed from
a different perspective. Nevertheless, this will have con-
sequences for the types of resource use that are included
in the determination of q.
Analysis
The ﬁrst step in the analysis of an economic equivalence
or superiority trial is the analysis of the difference in
costs between the treatments. To show equivalence
or noninferiority of costs, the conﬁdence interval
approach is used. Equivalence is demonstrated if the
conﬁdence interval around the difference in total costs
lies entirely between the equivalence margins –q and q.
A negative cost difference between the new intervention
and the control intervention implies cost savings and a
positive cost difference implies extra costs. Therefore,
noninferiority of costs is shown if the upper limit of the
conﬁdence interval of the difference in total costs is
smaller than q. Economically meaningful superiority is
shown if the upper limit of the conﬁdence interval
around the difference in costs is smaller than –q.
In our example trial mean (SD) total costs in the
standardized usual care group and in the standardized
usual care plus antidepressants group were €4668
(5654) and €5418 (6003), respectively. The mean dif-
ference in total costs was –€751 and the 95% conﬁ-
dence interval around this difference ranged from
–€3601 to €1522. The upper limit of the 95% conﬁ-
dence interval was greater than €500 (q), so noninfe-
riority for costs could not be shown.
Cost-Effectiveness Plane
The second and most important step in the analysis of
economic equivalence and noninferiority trials is the
joint analysis of costs and effects in a cost-effectiveness
Figure 1 Position of the conﬁdence interval (black horizontal bar) in
relation to –d, 0, and d with the appropriate conclusion for measures
where a higher score indicates improvement. *in these cases the conclu-
sion noninferior or nonsuperior can also be drawn. d = clinically accept-
able difference.
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analysis. Bootstrapping can be used to evaluate the
uncertainty surrounding the cost-effectiveness ratios.
To visualize this uncertainty, the incremental costs and
effects in all bootstrap samples are plotted on a cost-
effectiveness plane. Subsequently, the equivalence or
noninferiority margins, d (clinical) and q (economic),
can be presented in the cost-effectiveness plane (Figs 2
and 3). For the sake of clarity, the margins as drawn in
Figures 2 and 3 have no relation with a conﬁdence
interval around the Incremental Cost-Effectiveness
Ratio (ICER). Position of a cost-effect pair in the area
within the equivalence margins or noninferiority
margins indicates that the differences in costs and/or
effects for this pair are considered economically and/or
clinically unimportant, because these differences are
smaller than the predeﬁned margin. Equivalence with
regard to cost-effectiveness can be demonstrated if
100-a% of the cost-effect pairs lies in the area within
the equivalence margins (shaded area, Fig. 2). Nonin-
feriority with regard to cost-effectiveness can be dem-
onstrated if 100-a% of the cost-effect pairs lies right of
the noninferiority margin for effects and below the
noninferiority margin for total costs (shaded area,
Fig. 3). When using this method, it is possible that the
effects of the treatments are considered equivalent or
noninferior, but not the costs. In these cases the con-
clusion of the study is that equivalence or noninferior-
ity with regard to cost-effectiveness cannot be shown.
Figure 4 shows the cost-effectiveness plane of our
example trial for the improvement in quality-adjusted
life-years (QALYs) based on the EuroQol, including
the noninferiority margins. The noninferiority margin
for the improvement in QALYs was -0.03 and for
costs, as mentioned above, €500. We used a one-sided
a of 2.5%, so 97.5% of the cost-effect pairs had to be
situated in the noninferiority area to show noninferi-
ority. As indicated in the ﬁgure, 61% of the cost-effect
pairs was situated in the noninferiority area, so non-
inferiority with regard to cost-effectiveness for QALYs
could not be shown.
ICER
The traditional ICER may not be the best way to
present the relation between costs and effects in an
I
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-
Quadrant Costs Effects
A More expensive Equivalent
B More expensive Superior
C Equivalent Superior
D Equivalent Superior
E Cheaper Superior
F Cheaper Equivalent
G Cheaper Equivalent
H Cheaper Inferior
I Equivalent Inferior
J Equivalent Inferior
K More expensive Inferior
L More expensive Equivalent
Equivalent Equivalent
Figure 2 Presentation of equivalence margins in the cost-effectiveness
plane. DC = incremental costs; DE = incremental effects; d = equivalence
margins for effects; q = equivalence margin for costs.
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-
Quadrant Costs Effects
A Noninferior Inferior
B Noninferior Inferior
C More expensive Inferior
D More expensive Noninferior
E More expensive Noninferior
Noninferior Noninferior
Figure 3 Presentation of noninferiority margins in the cost-effectiveness
plane. DC = incremental costs; DE = incremental effects; d = noninferiority
margin for effects; q = noninferiority margin for costs.
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equivalence or noninferiority trial. The ICER is a con-
tinuous measure and corresponds to the slope of the
line through the origin of the cost-effectiveness plane
and through the point in the cost-effectiveness plane
that is deﬁned by the mean difference in costs and the
mean difference in effects between the two treatment
groups (point estimate of the ICER). In Figure 5a two
example ICERs (lines A: ICER = 20 and B: ICER = 2)
and two point estimates (points 1: DC = 400, DE = 20
and 2: DC = 100, DE = 5) are drawn. For every point
estimate on a line through the origin the ICER is equal.
In superiority research a judgment has to be made for
every point on the line whether the effects are worth
the costs. For example, for point 1 in Figure 5a: am I
willing to pay €400 to gain 20 effect units? Neverthe-
less, in equivalence and noninferiority research the
acceptable ICERs are limited by the equivalence or
noninferiority margins. For example, the point esti-
mates 1 and 2 on line A have the same ICER (20).
Nevertheless, point estimate 1 is not relevant in an
equivalence study, because the incremental costs are
€400 and therefore greater than the equivalence
margin for costs of €250, so this point estimate can
never be associated with two equivalent treatments
and line A is limited by the equivalence margins for
costs. Line B on the other hand is limited by the
equivalence margins for effects. The ICER drawn in
Figure 5b is on one side limited by the noninferiority
margin for costs and on the other side by the noninfe-
riority margin for effects.
Presentation
When presenting the results of an economic equiva-
lence or noninferiority trial, it is important to show the
conﬁdence intervals around the differences in costs and
effects. Costs, and therefore q, may vary in different
settings or countries. Presentation of the conﬁdence
interval around the difference in total costs allows the
reader to draw conclusions for a q that reﬂects his or
her speciﬁc circumstances. To determine what q is rel-
evant to the reader, the reader has to consider both the
resource use patterns and the unit costs used in his or
her situation.
Considering the uncertainty regarding q, we recom-
mend researchers to perform a sensitivity analysis in
which q is varied. This exploration of the inﬂuence of
q on the results is also important when no acceptable
difference in costs is deﬁned before the start of the
study. The probability that the reference treatment is
equivalent or noninferior to the other treatment for
various values of q, although d is kept constant, can be
drawn in a ﬁgure. This results in an equivalence or
noninferiority curve (Fig. 6). It is also possible to vary
d although q is kept constant. Nevertheless, generally
there will be less uncertainty surrounding d. Moreover,
a study will generally be sufﬁciently powered to show
equivalence for a certain d.
The curve in Figure 6 at ﬁrst sight resembles an
acceptability curve. Because acceptability curves focus
on the ICER as a continuous measure in relation to the
amount a policymaker is willing to pay to gain one
unit of effect, acceptability curves have no meaningful
interpretation in economic equivalence and non-
inferiority research. In economic equivalence and non-
inferiority research, two separate and independent
margins for costs and effects are deﬁned, and we are
interested in the proportion of cost-effect pairs that lies
in the equivalence or noninferiority area. If chosen well
the cost margin in itself incorporates some consider-
ation of the amount of money a policymaker is willing
to pay, or, in other words, considers (un)important.
It can be seen from Figure 6 that when q increases,
so does the probability to demonstrate noninferiority.
Given a particular noninferiority margin for effects (d),
the noninferiority curve in Figure 6 cuts the vertical
axis at the probability of noninferior costs if standard-
ized usual care alone is expected to have statistically
signiﬁcantly lower costs than standardized usual care
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Figure 4 Cost-effectiveness plane for the
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for standardized usual care in comparison with
standardized usual care plus antidepressants,
including the noninferiority margins. QALYs,
quality-adjusted life-years.
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plus antidepressants. In other words, the probability of
noninferior costs of standardized usual care alone in
comparison with standardized usual care plus antide-
pressants if q = €0. The curve is asymptoting to the
probability of noninferior effects given a particular d.
An equivalence curve cuts the vertical axis at the prob-
ability of equivalent costs if q = €0 and asymptotes to
the probability of equivalent effects given a particular
d.
Discussion
In this article we describe how methods for equiva-
lence and noninferiority trials can be applied to eco-
nomic evaluations in this type of research. Conclusions
are drawn using the position of a conﬁdence interval in
relation to a predeﬁned acceptable difference in costs
and effects. Cost-effectiveness planes make the evalu-
ation and interpretation of the results for both costs
and effects in an economic equivalence or noninferior-
ity trial simpler, as the proportion of cost-effect pairs in
the equivalence or noninferiority area can be estimated
at a glance. Equivalence or noninferiority curves indi-
cate the probability of equivalence or noninferiority
for a range of equivalence or noninferiority margins.
These curves show the uncertainty surrounding these
margins and are a useful tool when no acceptable
difference in costs has been speciﬁed before the start of
the study.
We have already stated in the main section that after
testing for equivalence or noninferiority, it is still pos-
sible to test for clinically or economically meaningful
superiority, using the conﬁdence interval approach.
This approach may also be relevant in traditional supe-
riority research. Evidence of a statistically signiﬁcant
difference does not imply that the difference found is
clinically important. By deﬁning a clinically important
difference, basing sample sizes on this difference, and
using the conﬁdence interval approach described here
to test for superiority, a decision can be given on the
clinical importance of the results found in the study.
We agree with Briggs and O’Brien [9] that in
economic evaluations the focus should be on cost-
effectiveness analyses and that the use of cost-
minimization analysis usually is not appropriate. They
point out that a cost-minimization analysis is only
appropriate in studies that have been designed to show
therapeutic equivalence. In this article we argue that in
economic evaluations accompanying clinical equiva-
lence or noninferiority studies, it is important to decide
before the start of the study on the appropriate eco-
nomic research question. In many cases it may be
useful to have the disposal of two clinically equivalent
treatments that are either economically equivalent (i.e.,
new treatment as expensive as old treatment) or eco-
nomically noninferior (i.e., new treatment not more
expensive than old treatment) to each other. In these
situations it is important that the equivalence margins
for costs and effects are deﬁned a priori. Analysis is
then based on the relationship between costs and
effects. Which one of two equivalent or noninferior
treatments is eventually chosen depends on other
factors than costs and effects. Side effects can play not
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Figure 5 (a) Examples of ICERs drawn in the cost-effectiveness plane for
an economic equivalence study. (b) Examples of ICERs drawn in the
cost-effectiveness plane for an economic noninferiority study. ICER, Incre-
mental Cost-Effectiveness Ratio.
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only an important role in this decision but also pref-
erences of patients and health-care professionals, as
well as the availability and burden of the treatments.
This means that it is particularly important in equiva-
lence research to record factors that may inﬂuence this
decision process, during the study.
A problemwith economic equivalence studies is that
to provide useful information for health policymakers
economic evaluations usually have a pragmatic study
design, so that they resemble routine clinical practice as
much as possible. This results in a diminished contrast
between the treatment groups, which conﬂicts with the
requirements for an equivalence trial, where diminish-
ing of the contrast increases the chance of ﬁnding
equivalence. The most common reason to perform an
equivalence or noninferiority trial is that there already
exists an effective treatment and that it is considered
unethical to withhold this effective treatment from
patients. When there is already some evidence for the
efﬁcacy of the new treatment (which must be the case
because this will concern phase III trials), an economic
equivalence or noninferiority trial is preferred over a
superiority trial. When performing an (economic)
equivalence or noninferiority trial care has to be taken
that the study protocol is followed strictly.
To calculate sample sizes for equivalence and non-
inferiority trials, researchers can use standard sample
size calculations [10,11]. Nevertheless, the resulting
sample sizes usually need to be larger than in superi-
ority trials, because the chosen clinically and economi-
cally important differences should generally be smaller
than in a superiority trial [1]. In economic equivalence
or noninferiority trials even larger sample sizes are
needed, because the distribution of cost data typically
is heavily skewed [12]. Often it will be not possible for
ﬁnancial, logistic or ethical reasons to include as many
patients as are needed for the trial to have sufﬁcient
power for economic outcomes. Therefore, a common
problem in economic evaluations is that they are
underpowered. The choice of q is inextricably bound
up with the power of the study. Nevertheless, the
choice of q is difﬁcult; if q is chosen too small, this will
lead to unnecessarily large trials. The other way round,
if q is chosen too large, this will lead to a conclusion
of equivalence for substantially different treatments.
Some advice on how to determine q is given in this
article. To investigate the uncertainty surrounding q,
we propose to draw an equivalence or noninferiority
curve. In this curve the probability of equivalent or
noninferior cost-effectiveness is drawn for varying
values of q, although d is kept constant.
Conclusion
The availability of effective treatments for many dis-
eases means that equivalence and noninferiority trials
are becoming increasingly important in health-care
research [13–15]. These trials may inﬂuence health
policy and should be accompanied by an economic
evaluation. It is important to decide before the start of
the study on the appropriate research question for the
economic evaluation. In many cases the objective of
the economic evaluation will be to show equivalent or
noninferior cost-effectiveness of the treatments. In this
article we showed how cost-effectiveness techniques
can be used to show noninferior or equivalent costs
and cost-effectiveness. This has major implications for
the design, analysis and report of the economic evalu-
ation. The most important consequence of such a
research question is that acceptable differences in costs
and effects must be deﬁned a priori. Analysis of effects
and costs is based on the position of conﬁdence inter-
vals in relation to these acceptable differences. Cost-
effectiveness planes prove to be a valuable tool in the
interpretation of the results for both costs and effects
in an economic equivalence or noninferiority trial.
Equivalence or noninferiority curves show the uncer-
tainty surrounding the equivalence or noninferiority
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Figure 6 Noninferiority curve given a noninfe-
riority margin of -0.03 for improvement in
QALYs based on the EuroQol for standardized
usual care in comparison with standardized
usual care plus antidepressants. In this ﬁgure, the
probability is drawn that counseling alone is
noninferior to counseling plus antidepressants
for various values of q although d is kept con-
stant. QALYs, quality-adjusted life-years.
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margins and are also useful when no acceptable differ-
ence in costs has been speciﬁed in advance of the study.
Source of ﬁnancial support: no funding was acquired to assist
in the preparation of this manuscript. Conﬂicts of interest:
none declared.
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